|
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) is hosting "Bioterrorism
Prevention, Preparedness and Response," a forum organized for members of
the North Atlantic Treaty Organization (NATO) Parliamentary Assembly
(PA) to raise global awareness of the importance of biopreparedness. The
visiting delegation is composed of parliamentarians from Canada,
Estonia, France, Finland, Germany, Greece, Italy, Hungary, Lithuania,
the Netherlands, Norway, Romania, Poland, Portugal, Turkey, Sweden,
Slovenia, Spain, and the United Kingdom.
"Emergent commends NATO parliamentarians for advancing the international
dialogue on biopreparedness," said Allen Shofe, senior vice president
public affairs, Emergent BioSolutions. "We are pleased to share our
knowledge based on Emergent's extensive experience in the development,
manufacture, and delivery of medical countermeasures that are critical
to the U.S. government's biodefense infrastructure."
The forum features biodefense expert Dr. Robert Kadlec, Director of PRTM
Biodefense and Public Health Practice, who will discuss the United
States' approach to bioterrorism prevention, including best practices
and strategies such as funding, development, and manufacture of
biodefense medical countermeasures, creation of strategic stockpiles,
and cooperation within the international community.
Emergent BioSolutions' senior management team, headed by Daniel J.
Abdun-Nabi, President and Chief Operating Officer, Dr. Tevi Troy, Senior
Visiting Fellow at the Hudson Institute and former Deputy Director of
the U.S. Department of Health and Human Services, and Dr. Barry Kellman,
President of the International Security and Biopolicy Institute (ISBI)
are among the attendees. The forum is taking place in Washington, D.C.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
About the NATO Parliamentary Assembly
The NATO Parliamentary Assembly is the inter-parliamentary organization
of legislators from the member countries of the North Atlantic Alliance
as well as 14 associate members. The Assembly provides a critical forum
for international parliamentary dialogue on an array of security,
political and economic matters. For more information, visit www.nato-pa.int.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
+1-301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
+1-301-795-1800
SchmittT@ebsi.com |